Avermectin inhibits Mucor miehei and Artemia salina chitin synthesis and to a degree DNA synthesis in the former. The antibiotic interferes with chitin turnover in brine shrimp and inhibits Streptomyces antibioticus chitinase activity in vitro. In light of the proposed mode of action of avermectin and the anomolies in the literature, it is proposed that avermectin can kill susceptible organisms not only by a neurotoxic mechanism but also by inhibiting chitin turnover and synthesis at low concentration and thus the molting/ecdysis process.
All bacteria and the yeast, Candida albicans, were resistant to avermectin while the three fungi, Aspergillus niger, Piricularia oryzae and M. miehei were susceptible to the antibiotic (Table 1) . Brine shrimp were also susceptible to avermectin exhibiting an LC,, of 0.8 ng/ml (data not shown).
Effect of Avermectin an Active Transport and
Macromolecular Synthesis in M. miehei and A. salina Table 2 presents data on the effect of both low and high concentrations of avermectin on the various cell processes in the two susceptible organism. The concentrations chosen were at or near the minimal inhibitory concentration and ten-fold above these values. While most cell processes were relatively unaffected by the antibiotic, DNA synthesis in M. miehei and wall synthesis in both organisms were particularly susceptible. To confirm that incorporation of [3H]-N-acetylglucosamine into TCAinsoluble material did measure chitin synthesis, we determined the effect of polyoxin D on this activity"). Controls had equal volumes of methanol.
Chitin Turnover in Brine Shrimp
Since avermectin appeared to interfere with chitin synthesis, it is conceivable that it might interfere with chitin turnover. Fig. 2 shows the effect of avermectin on stability of chitin in brine shrimp.
As is evident, avermectin at 10 ng/ml slowed down the rate of liberation of radioactive from TCAinsoluble material i.e. slowed down chitin turnover.
In separate experiments not shown polyoxin D (1001zg/ml) also slowed down chitin turnover although the addition of both avermectin and polyoxin D did not show a synergistic effect. Avermectin at various concentrations was incubated at 30°C with a Streptomycete chitinase in the presence of the chromogenic substrate, Y-chitinred. The absorbance of the suspension was monitored continuously at 510 nm. Enzyme activities were calculated from the linear portion of the curves and were converted to % of control, (enzyme activity recorded for controls were always in the 0.600.72 units/cuvette). VOL Since avermectin has been shown to inhibit chitin synthetase and chitin turnover, it is conceivable that it might be an effective inhibitor of the enzyme chitinase. Unfortunately, since a source of active chitinase from an invertebrate is not available commercially, we chose to use the enzyme from S.
antibioticus (Calbiochem) as a model system. Using a colorimetric assay described by others9), we investigated the effect of avermectin on this enzyme activity. From Fig. 3 , it is evident that avermectin was a potent inhibitor and exhibited an apparent K of approximately 2 -3 yg/ml against chitinase.
Discussion
Research workers at Merck have shown convincing evidence that avermectin is capable of binding to rat brain membranes and eliciting, an alteration in the binding of GABA4). Using a relatively crude membrane system from rat brain, they have been able to detect a picrotoxin, bicuculline sensitive, Cl-dependent stimulation of GABA binding to its receptor4). This enhancement is associated with an increase in number of receptors but no alteration in their affinity indicating that avermectin exposes more receptors and does not expose a new species. However, these studies employ a test organism, the rat, that is intrinsically resistant to avermectin. Further they propose that this enhancement of GABA binding observed in vitro will result in an increase in Cl-permeability of the membrane resulting in loss of action potential in the neuron, loss of motor function and eventual paralysis in vivo5,6) . This increase in Cl-permeability and loss of motor function has been seen in studies employing avermectin sensitive organisms, a crustacean, and a nematode5,6). In further support of their GABA receptor target model for avermectin toxicity, they cite their studies of various analogues of avermectin. While their conclusions are supported by their data for four of the five analogues of avermectin, the data from the aglycone form of avermectin is at variance (Table 3) . This analogue is a relatively effective agent against their model pest (58 %), Caenorhabditis elegans while it is relatively inactive in their receptor assay (4%) when compared with avermectin. This suggests that while their model may explain some of the data, there are situations where an alternative mode of action is possible.
In this paper, we have described studies where we have examined the sensitivity of an invertebrate, A. salina, the brine shrimp, and M. miehei, a fungus to avermectin. In both cases, the organisms are avermectin sensitive, yet while the former should contain GABA receptors associated with a nervous system, the latter, containing no nervous system, should possess no neuronal GABA receptors. Thus, it is logical to suppose that avermectin is capable of killing Mucor, at least, in another manner. That avermectin inhibited the incorporation of N-acetylglucosamine into TCA-insoluble material (chitin) in both organisms would indicate that chitin synthesis could be a target process in both organism. This association was strengthened by the findings that avermectin slowed down chitin turnover in brine shrimp and effectively inhibited chitinase activity in an in vitro assay system. Thus, avermectin appears to act as a chitin metabolism inhibitor. Examination of two avermectin analogues, ivermectin and NT: Not tested (analogues not available). Data on AVM receptor activity and C. elegans toxicity from PONG and WANG11), other data from this paper and unpublished data. milbemycin (the aglycone form of avermectin) indicates that the chitin metabolism inhibitor action of avermectin and analogues appears to explain the discrepancies noted in the Merck data (Table 3) . Thus, the lack of activity of the aglycone form of avermectin in the receptor assay yet its effective ability to kill the model pest, C. elegans, can be accounted for by its strong activity versus chitin synthesis, turnover and degradation processes (Table 3) . While it is likely that avermectin interacts directly with the chitinase enzyme or binds to substrate preventing its interaction with the enzyme (the assays were performed in vitro using a purified enzyme system), it is not clear whether the effect of the antibiotic on chitin synthesis and turnover is direct or by indirect means such as via hormone control. To determine the precise mechanism would require a more detailed in vitro study. Table 4 presents the spectrum of activity of avermectin against a number of organisms ranging from a mammal (rat) to a fungus (M. miehei). As can be seen, the specificity observed for avermectin correlates with the presence of GABA receptors in all organisms studied except rat which is avermectin resistant and possesses GABA receptors and the fungus that is avermectin sensitive and does not contain GABA receptors. However, rat GABA receptors are in the central nervous system protected by a blood brain barrier. This table also presents data on the presence of chitin in these organisms. As can be seen, the chitin target model fits the data as well as, if not better than, the GABA receptor target model, particularly in cases of the rat and fungus. Clearly, we believe the chitin metabolism target model is a viable alternative mechanism for the mode of action of avermectin. We feel that at high concentrations avermectin may very well kill susceptible organisms by paralysis but at low levels the action is by disturbance of chitin metabolism perhaps during the ecdysis process.
